Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 207127 NA

First Posted Date: 2012-05-25

Last Posted Date: 2016-03-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT01605461

Locations: 🇺🇸
1241.22.001 Boehringer Ingelheim Investigational Site, Madison, Wisconsin, United States

Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor and Assessment of Ticagrelor Interaction Potential With Dabigatran

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ticagrelor
Drug: dabigatran etexilate

First Posted Date: 2012-05-10

Last Posted Date: 2013-08-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT01595854

Locations: 🇩🇪
1160.141.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1015550
Drug: BI 101550
Drug: Placebo

First Posted Date: 2012-05-09

Last Posted Date: 2015-12-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 70

Registration Number: NCT01594515

Locations: 🇩🇪
1305.1.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma

Phase 1

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Nintedanib low dose
Drug: Nintedanib medium dose
Drug: Nintedanib high dose

First Posted Date: 2012-05-08

Last Posted Date: 2016-02-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT01594125

Locations: 🇯🇵
1199.120.001 Boehringer Ingelheim Investigational Site, Chuo-ku, Tokyo, Japan
🇯🇵
1199.120.005 Boehringer Ingelheim Investigational Site, Fukuoka, Fukuoka, Japan
🇯🇵
1199.120.003 Boehringer Ingelheim Investigational Site, Nagoya, Aichi, Japan

and more 2 locations

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 163538 XX

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo to BI 163538 XX
Drug: BI 163538 XX

First Posted Date: 2012-04-30

Last Posted Date: 2013-10-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT01587391

Locations: 🇩🇪
1291.1.1 Boehringer Ingelheim Investigational Site, Neuss, Germany

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 187004 CL

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 187004 CL
Drug: Placebo to BI 187004 CL

First Posted Date: 2012-04-30

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 72

Registration Number: NCT01587417

Locations: 🇩🇪
1307.1.1 Boehringer Ingelheim Investigational Site, Neuss, Germany

Safety Tolerability and Pharmacokinetic of BI 411034

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 411034
Drug: Placebo

First Posted Date: 2012-04-20

Last Posted Date: 2017-08-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 62

Registration Number: NCT01581684

Locations: 🇩🇪
1308.1.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: BI10773

First Posted Date: 2012-04-20

Last Posted Date: 2017-08-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT01581658

Locations: 🇯🇵
1245.53.001 Boehringer Ingelheim Investigational Site, Kurume, Fukuoka, Japan

Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Linagliptin/metformin
Drug: Metformin
Drug: Linagliptin

First Posted Date: 2012-04-20

Last Posted Date: 2013-08-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT01581931

Locations: 🇩🇪
1288.20.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: BI 201335

First Posted Date: 2012-04-19

Last Posted Date: 2015-07-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT01580306

Locations: 🇩🇪
1220.58.1 Boehringer Ingelheim Investigational Site, Kiel, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy